US OptionsDetailed Quotes
CPRX250117P22500
- 0.06
- 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
0.00Open0.06Pre Close0 Volume124 Open Interest22.50Strike Price0.00Turnover1576.23%IV1.88%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type-0.2231Delta0.6454Gamma381.17Leverage Ratio-115.8779Theta0.0000Rho-85.03Eff Leverage0.0001Vega
Catalyst Pharmaceuticals Stock Discussion
Sign in to post a comment
$Catalyst Pharmaceuticals (CPRX.US)$ $Teva Pharmaceutical Industries (TEVA.US)$
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
Catalyst Pharmaceuticals (CPRX) and its licensor SERB S.A. have reached a settlement agreement with Teva Pharmaceuticals regarding patent litigation over FIRDAPSE® (amifampridine). The litigation was initiated after Teva filed an Abbreviated New Drug Application seeking to market a generic version o...
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
Catalyst Pharmaceuticals (CPRX) and its licensor SERB S.A. have reached a settlement agreement with Teva Pharmaceuticals regarding patent litigation over FIRDAPSE® (amifampridine). The litigation was initiated after Teva filed an Abbreviated New Drug Application seeking to market a generic version o...
2
7
$Catalyst Pharmaceuticals (CPRX.US)$ $Teva Pharmaceutical Industries (TEVA.US)$ Reuters
1 min ago
Catalyst Pharmaceuticals Announces Settlement of Firdapse® (Amifampridine) Patent Litigation With Teva Pharmaceuticals
1 min ago
Catalyst Pharmaceuticals Announces Settlement of Firdapse® (Amifampridine) Patent Litigation With Teva Pharmaceuticals
$Catalyst Pharmaceuticals (CPRX.US)$ Catalyst Pharmaceuticals Enters Exclusive License, Supply And Commercialization Agreement Granting Kye Pharmaceuticals Canadian Rights To AGAMREE For Duchenne Muscular Dystrophy
See remaining FDA PDUFAs in May 👀👇
$Bristol-Myers Squibb (BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna (MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals (CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro...
$Bristol-Myers Squibb (BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna (MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals (CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro...
9
1
1
$Catalyst Pharmaceuticals (CPRX.US)$ May 08 (Reuters) - Catalyst Pharmaceuticals Q1 Net Income USD 23.3 Million.
Q1 Adjusted Net Income USD 46.8 Million Vs. Ibes Estimate USD 23.7 Million
Q1 Operating Income USD 27.1 Million Vs. Ibes Estimate USD 25.1 Million
Outlook FY Revenue USD 455-475 Million
Q1 Adjusted Net Income USD 46.8 Million Vs. Ibes Estimate USD 23.7 Million
Q1 Operating Income USD 27.1 Million Vs. Ibes Estimate USD 25.1 Million
Outlook FY Revenue USD 455-475 Million
The absence of insider buying at Catalyst Pharmaceuticals over the past year is concerning. However, the high level of insider ownership indicates alignment with shareholder interests. Insider selling, even below the current price, raises questions about their view on the company's valuation.
1
No comment yet
Mangkawat : red day but its still stable
Jaguar8 OP Mangkawat : Nothing big news for me on this one unless it comes with a monetary award
Mangkawat Jaguar8 OP : how about $BioLine Rx (BLRX.US)$ bioline rx. any news ? drop and drop.
Jaguar8 OP Mangkawat : It made an offering days ago
Mangkawat Jaguar8 OP : but price look like on risk to be delist. still below $1 .
View more comments...